SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Innovator ETFs Trust - Innovator U.S. Equity Buffer ETF - September

Invesco Exchange-Traded Self-Indexed Fund Trust - Invesco BulletShares 2026 High Yield Corporate Bond ETF

Invesco BulletShares 2026 High Yield Corporate Bond ETF

Invesco Exchange-Traded Self-Indexed Fund Trust - Invesco BulletShares 2027 High Yield Corporate Bond ETF

Invesco BulletShares 2027 High Yield Corporate Bond ETF

Invesco Exchange-Traded Self-Indexed Fund Trust - Invesco BulletShares 2028 High Yield Corporate Bond ETF

Invesco BulletShares 2028 High Yield Corporate Bond ETF

Invesco Exchange-Traded Self-Indexed Fund Trust - Invesco BulletShares 2026 Municipal Bond ETF

Invesco BulletShares 2026 Municipal Bond ETF

Invesco Exchange-Traded Self-Indexed Fund Trust - Invesco BulletShares 2027 Municipal Bond ETF

Invesco BulletShares 2027 Municipal Bond ETF

Invesco Exchange-Traded Self-Indexed Fund Trust - Invesco BulletShares 2028 Municipal Bond ETF

Invesco BulletShares 2028 Municipal Bond ETF

Invesco Exchange-Traded Self-Indexed Fund Trust - Invesco BulletShares 2029 Municipal Bond ETF

Invesco BulletShares 2029 Municipal Bond ETF

Invesco Exchange-Traded Self-Indexed Fund Trust - Invesco BulletShares 2030 Municipal Bond ETF

Invesco BulletShares 2030 Municipal Bond ETF

BlackRock ETF Trust - iShares U.S. Thematic Rotation Active ETF

BlackRock ETF Trust - BlackRock Future U.S. Themes ETF

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today...

Viridian Therapeutics (NASDAQ:VRDN) Given "Buy" Rating at Needham & Company LLC

Needham & Company LLC reaffirmed a "buy" rating and set a $32.00 price target on shares of Viridian Therapeutics in a research report on Tuesday...

Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock

Promising Biotech Stocks To Watch Today - May 5th

Vertex Pharmaceuticals, Danaher, and Viridian Therapeutics are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that research, develop and commercialize biological products and technologiessuch as novel drugs, gene thera...

Viridian Therapeutics (NASDAQ:VRDN) Shares Gap Up  on Strong Earnings

Viridian Therapeutics (NASDAQ:VRDN) Shares Gap Up Following Earnings Beat...

<ul class="summary-bullets"><li>The therapy delivered proptosis response rates 50% at week 24 for dosing every four weeks, compared with 15% for placebo.</li><li>Viridian is expected to file an application for the therapy with the FDA by the first quarter of 2027.</li><li>Q1 loss came in at $0.90 per share, lower than Wall Street’s estimate of $1.08 per share, according to Fiscal.ai data.</li></ul>Shares of Viridian Therapeutics (VRDN) jumped more than 35% on Tuesday following strong late-stage results for its thyroid eye disease treatment and a better-than-feared first-quarter loss.<a href="https://stocktwits.com/symbol/VRDN">VRDN shares</a> recorded their biggest single-day gain since Aug. 15, 2022.<h2 class="st-heading-2">VRDN’s Elegrobart Shines In Phase 3 Trial</h2>Viridian said that Elegrobart, its Thyroid Eye Disease (TED) therapy, met its primary endpoint in the REVEAL-2 Phase 3 study, highlighting meaningful improvements across key measures in patients with chronic disease.The therapy delivered proptosis response rates (PRR) of 50% and 54% at week 24 for dosing every four and eight weeks, respectively, compared with 15% for placebo. The PRR is a measure of reduction in eye protrusion.The drug also showed benefits in reducing double vision, with the four-week group achieving a 61% diplopia response rate versus 38% in the placebo group. Elegrobart was generally well tolerated, with most side effects mild and in line with expectations for its drug class.Rates of hearing-related issues were low, and no treatment-related serious adverse events were reported. Notably, 91% of patients completed the full course of treatment. A regulatory filing with the U.S. Food and Drug Administration (FDA) remains on track for the first quarter (Q1) of 2027.<h2 class="st-heading-2">VRDN’s Q1 Loss Widens But Tops Estimates</h2>Viridian also reported its Q1 results on Tuesday. While its loss widened to $0.90 per share from $0.87 per share, it beat Wall Street’s estimate of $1.08 per share, according to Fiscal.ai data.Research and development (R&amp;D) expenses came in at $77.6 million for the quarter, edging up from $76.8 million a year ago, primarily driven by higher manufacturing-related costs.Viridian also added that its other TED therapy, Veligrotug, is under ‘Priority Review’ by the FDA, with a decision expected by June 30, 2026. The company has completed hiring its field teams and has its supply, manufacturing, and distribution systems ready for the launch.<h2 class="st-heading-2">Retail Sees VRDN’s Therapy Outperforming Amgen’s Tepezza</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘high’ message volumes.One user explained why Elegrobart could see better uptake than Amgen’s Tepezza.<stembedurl>https://stocktwits.com/Sjskdhai/message/652274493</stembedurl>Another user expects the stock to climb to at least $20 by the end of the session. It is currently at $19.<stembedurl>https://stocktwits.com/Drugtrade/message/652281724</stembedurl>The stock has declined more than 40% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-immunitybio-aua-meeting-anktiva-bcg-data-next-week/cZQwCMWRe9R">IBRX Stock In Spotlight: ImmunityBio To Unveil Fresh Anktiva And BCG Data Next Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

VRDN Stock Records Biggest Single Day Gains In 45 Months – And It’s Not Just Due To A Better-Than-Feared Q1 Loss

Viridian said that Elegrobart, its Thyroid Eye Disease therapy, met its primary endpoint in the REVEAL-2 Phase 3 study.

Equity

Markets On Fire: Biotech Breakthroughs and AI Mega-Deals Move Wall Street

$CLRB, $NTHI, $BLZE, $DGXX, $VRDN, $CYTK are among today's leading stocks

Viridian Therapeutics (NASDAQ:VRDN) Issues Earnings Results

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.16. Viridian Therapeutics had a negative return on equity of 83.25% and a...

Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the first quarter ended March 31...

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have received a consensus rating of "Moderate Buy" from the fifteen research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned...

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

Stocktwits

Stocktwits Polls

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.97	--	--	N/A
Q1 '26	-$1.08	-$0.90	16.74%	BEAT
Q4 '25	-$0.98	-$1.08	-10.24%	MISSED
Q3 '25	-$1.02	-$0.34	66.62%	BEAT
Q2 '25	-$1.00	-$1.00	0.09%	BEAT

VRDN
Viridian Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Latest VRDN News

VRDNViridian Therapeutics Inc